Entropy Technologies LP Buys 53,867 Shares of TG Therapeutics, Inc. $TGTX

Entropy Technologies LP increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 822.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,415 shares of the biopharmaceutical company’s stock after buying an additional 53,867 shares during the quarter. Entropy Technologies LP’s holdings in TG Therapeutics were worth $1,801,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Danske Bank A S bought a new position in shares of TG Therapeutics during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. lifted its holdings in shares of TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 732 shares during the period. Bessemer Group Inc. boosted its stake in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Trading Up 1.6%

Shares of NASDAQ TGTX opened at $50.30 on Tuesday. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $50.60. The company has a 50-day moving average of $38.72 and a two-hundred day moving average of $33.24. The company has a market cap of $7.70 billion, a PE ratio of 17.59 and a beta of 1.68. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business’s revenue for the quarter was up 69.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.03 EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post 1.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a research report on Wednesday, May 27th. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.